Brought to you by 
Oxford Finance leads Aerovance's $10mm debt sale
13 Apr 2009
Executive Summary
Aerovance (respiratory disorder and eczema compounds) raised $10mm by selling debt to a group led by Oxford Finance and including Silicon Valley Bank and Comerica Bank. The company may draw down another $10mm when it reaches undisclosed corporate milestones. The money will go towards finding a global partner for the recombinant protein Aerovant, in Phase IIa for asthma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Nonconvertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oxford Finance leads Aerovance's $10mm debt sale
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice